Skip to navigation Skip to content
Actavalon

Actavalon

Actavalon is an oncology-focused company targeting two fundamental cancer pathways .

Toggle navigation menu
  • About Us
  • Business Development
  • Team
    • Management Team
    • Board of Directors
  • The Science
    • Small Molecule p53 Modulators
    • Selective Aryl Hydrocarbon Receptor Modulators (SAhRM)
  • Press
  • Contact Us

Contact us

info@actavalon.com

Contact Us

Actavalon

Category: Press

Actavalon Announces Appointment of Dr. John Hood to Its Board of Directors

August 14, 2018   /   Press

SAN DIEGO, August 14, 2018 (PR NEWSWIRE) –Actavalon, Inc., a preclinical-stage biotechnology company focused on developing small molecules in the field of oncology, today announced it has appointed Dr. John Hood to its Board of Directors. “It’s a genuine honor to join the board of Actavalon.  Actavalon is developing small molecule therapies for the some […]

Read more

Recent Posts

  • Actavalon Announces Appointment of Dr. John Hood to Its Board of Directors
Actavalon

Contact Us

We are located in the JLABS incubator on the Johnson & Johnson Innovation Labs campus in San Diego, California.

info@actavalon.com

© 2018 Actavalon. All Rights Reserved.